Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24 vs 48 Weeks of PEG-IFN alpha-2a + Ribavirin in HCV Genotype 2/3 Relapsers
NCT01517308Phase 3Withdrawn
- Sponsor
- University of Naples Federico II
- Start
- May 2012
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (2 arms), sponsored by University of Naples Federico II. Primary endpoint: Sustained Virological Response. Planned start May 2012; status: withdrawn.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01517308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01517308.